Global Gastroparesis Drugs Market

Gastroparesis Drugs Comprehensive Study by Type (Prokinetic Agents, Antiemetic Agents, Botulinum Toxin Injection, Other), Application (Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-Surgical Gastroparesis), End-users (Hospitals, Clinics, Ambulatory Surgical Centres, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online, Others), Diagnosis (Gastric Emptying Tests (Scintigraphy and Breath tests), Upper gastrointestinal (GI) endoscopy, Ultrasound) Players and Region - Global Market Outlook to 2030

Gastroparesis Drugs Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 3.53%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Gastroparesis Drugs
Gastroparesis is a disease of the muscles of the stomach or the nerves controlling the muscles that affect the normal spontaneous movement of the muscles (motility). This condition results into inadequate grinding of food by the stomach, and poor emptying of food from the stomach into the intestine. This condition is generally treated with nutritional support, drugs that stimulate the muscle to work, drugs for treating nausea and vomiting, and, less often, electrical pacing, and surgery.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR3.53%


The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Gastroparesis Drugs market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Allergan, Plc. (Ireland), Abbott Laboratories (Abbott Arzneimittel GmbH) (United States), AstraZeneca Plc. (United Kingdom), Cadila Pharmaceuticals Ltd. (India), GlaxoSmithKline Plc. (United Kingdom), Neurogastrx, Inc. (United States), Valeant Pharmaceuticals International, Inc. (Canada), Theravance Biopharma (United Kingdom) and Johnson & Johnson (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are ETX Pharma, Inc. (United States) and Evoke Pharma (United States).

Segmentation Overview
AMA Research has segmented the market of Global Gastroparesis Drugs market by Type (Prokinetic Agents, Antiemetic Agents, Botulinum Toxin Injection and Other), Application (Diabetic Gastroparesis, Idiopathic Gastroparesis and Post-Surgical Gastroparesis) and Region.



On the basis of geography, the market of Gastroparesis Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End-users, the sub-segment i.e. Hospitals will boost the Gastroparesis Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Gastroparesis Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Diagnosis, the sub-segment i.e. Gastric Emptying Tests (Scintigraphy and Breath tests) will boost the Gastroparesis Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Technological Advancements in the Medical Science

Market Growth Drivers:
Increased Prevalence of DIabetes among People and Rise in the Number of Surgeries Performed Worldwide

Challenges:
Time-consuming Regulatory Process

Restraints:
Side Effects of the Gastroparesis Drugs

Opportunities:
Growth in the Geriatric Population Worldwide and Growing Healthcare Sector Worldwide

Market Leaders and their expansionary development strategies
In August 2021, Teva Pharmaceuticals announces the acquisition of Takeda Pharmaceuticals' non-core assets, including their portfolio of gastroparesis drugs.
In June 2023, Enteris Biopharma receives FDA approval for its new delayed-release formulation of domperidone, specifically designed for the treatment of gastroparesis.


Key Target Audience
Gastroparesis Drugs Manufacturers, Raw Material Suppliers', Distributors, Emerging Companies, Research Professionals and End-users

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Prokinetic Agents
  • Antiemetic Agents
  • Botulinum Toxin Injection
  • Other
By Application
  • Diabetic Gastroparesis
  • Idiopathic Gastroparesis
  • Post-Surgical Gastroparesis
By End-users
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centres
  • Others

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online
  • Others

By Diagnosis
  • Gastric Emptying Tests (Scintigraphy and Breath tests)
  • Upper gastrointestinal (GI) endoscopy
  • Ultrasound

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of DIabetes among People
      • 3.2.2. Rise in the Number of Surgeries Performed Worldwide
    • 3.3. Market Challenges
      • 3.3.1. Time-consuming Regulatory Process
    • 3.4. Market Trends
      • 3.4.1. Technological Advancements in the Medical Science
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Gastroparesis Drugs, by Type, Application, End-users, Distribution Channel, Diagnosis and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Gastroparesis Drugs (Value)
      • 5.2.1. Global Gastroparesis Drugs by: Type (Value)
        • 5.2.1.1. Prokinetic Agents
        • 5.2.1.2. Antiemetic Agents
        • 5.2.1.3. Botulinum Toxin Injection
        • 5.2.1.4. Other
      • 5.2.2. Global Gastroparesis Drugs by: Application (Value)
        • 5.2.2.1. Diabetic Gastroparesis
        • 5.2.2.2. Idiopathic Gastroparesis
        • 5.2.2.3. Post-Surgical Gastroparesis
      • 5.2.3. Global Gastroparesis Drugs by: End-users (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinics
        • 5.2.3.3. Ambulatory Surgical Centres
        • 5.2.3.4. Others
      • 5.2.4. Global Gastroparesis Drugs by: Distribution Channel (Value)
        • 5.2.4.1. Hospital Pharmacies
        • 5.2.4.2. Retail Pharmacies
        • 5.2.4.3. Online
        • 5.2.4.4. Others
      • 5.2.5. Global Gastroparesis Drugs by: Diagnosis (Value)
        • 5.2.5.1. Gastric Emptying Tests (Scintigraphy and Breath tests)
        • 5.2.5.2. Upper gastrointestinal (GI) endoscopy
        • 5.2.5.3. Ultrasound
      • 5.2.6. Global Gastroparesis Drugs Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Gastroparesis Drugs (Volume)
      • 5.3.1. Global Gastroparesis Drugs by: Type (Volume)
        • 5.3.1.1. Prokinetic Agents
        • 5.3.1.2. Antiemetic Agents
        • 5.3.1.3. Botulinum Toxin Injection
        • 5.3.1.4. Other
      • 5.3.2. Global Gastroparesis Drugs by: Application (Volume)
        • 5.3.2.1. Diabetic Gastroparesis
        • 5.3.2.2. Idiopathic Gastroparesis
        • 5.3.2.3. Post-Surgical Gastroparesis
      • 5.3.3. Global Gastroparesis Drugs by: End-users (Volume)
        • 5.3.3.1. Hospitals
        • 5.3.3.2. Clinics
        • 5.3.3.3. Ambulatory Surgical Centres
        • 5.3.3.4. Others
      • 5.3.4. Global Gastroparesis Drugs by: Distribution Channel (Volume)
        • 5.3.4.1. Hospital Pharmacies
        • 5.3.4.2. Retail Pharmacies
        • 5.3.4.3. Online
        • 5.3.4.4. Others
      • 5.3.5. Global Gastroparesis Drugs by: Diagnosis (Volume)
        • 5.3.5.1. Gastric Emptying Tests (Scintigraphy and Breath tests)
        • 5.3.5.2. Upper gastrointestinal (GI) endoscopy
        • 5.3.5.3. Ultrasound
      • 5.3.6. Global Gastroparesis Drugs Region
        • 5.3.6.1. South America
          • 5.3.6.1.1. Brazil
          • 5.3.6.1.2. Argentina
          • 5.3.6.1.3. Rest of South America
        • 5.3.6.2. Asia Pacific
          • 5.3.6.2.1. China
          • 5.3.6.2.2. Japan
          • 5.3.6.2.3. India
          • 5.3.6.2.4. South Korea
          • 5.3.6.2.5. Taiwan
          • 5.3.6.2.6. Australia
          • 5.3.6.2.7. Rest of Asia-Pacific
        • 5.3.6.3. Europe
          • 5.3.6.3.1. Germany
          • 5.3.6.3.2. France
          • 5.3.6.3.3. Italy
          • 5.3.6.3.4. United Kingdom
          • 5.3.6.3.5. Netherlands
          • 5.3.6.3.6. Rest of Europe
        • 5.3.6.4. MEA
          • 5.3.6.4.1. Middle East
          • 5.3.6.4.2. Africa
        • 5.3.6.5. North America
          • 5.3.6.5.1. United States
          • 5.3.6.5.2. Canada
          • 5.3.6.5.3. Mexico
    • 5.4. Global Gastroparesis Drugs (Price)
      • 5.4.1. Global Gastroparesis Drugs by: Type (Price)
  • 6. Gastroparesis Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Allergan, Plc. (Ireland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Abbott Laboratories (Abbott Arzneimittel GmbH) (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. AstraZeneca Plc. (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Cadila Pharmaceuticals Ltd. (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GlaxoSmithKline Plc. (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Neurogastrx, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Valeant Pharmaceuticals International, Inc. (Canada)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Theravance Biopharma (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Johnson & Johnson (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Gastroparesis Drugs Sale, by Type, Application, End-users, Distribution Channel, Diagnosis and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Gastroparesis Drugs (Value)
      • 7.2.1. Global Gastroparesis Drugs by: Type (Value)
        • 7.2.1.1. Prokinetic Agents
        • 7.2.1.2. Antiemetic Agents
        • 7.2.1.3. Botulinum Toxin Injection
        • 7.2.1.4. Other
      • 7.2.2. Global Gastroparesis Drugs by: Application (Value)
        • 7.2.2.1. Diabetic Gastroparesis
        • 7.2.2.2. Idiopathic Gastroparesis
        • 7.2.2.3. Post-Surgical Gastroparesis
      • 7.2.3. Global Gastroparesis Drugs by: End-users (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinics
        • 7.2.3.3. Ambulatory Surgical Centres
        • 7.2.3.4. Others
      • 7.2.4. Global Gastroparesis Drugs by: Distribution Channel (Value)
        • 7.2.4.1. Hospital Pharmacies
        • 7.2.4.2. Retail Pharmacies
        • 7.2.4.3. Online
        • 7.2.4.4. Others
      • 7.2.5. Global Gastroparesis Drugs by: Diagnosis (Value)
        • 7.2.5.1. Gastric Emptying Tests (Scintigraphy and Breath tests)
        • 7.2.5.2. Upper gastrointestinal (GI) endoscopy
        • 7.2.5.3. Ultrasound
      • 7.2.6. Global Gastroparesis Drugs Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Gastroparesis Drugs (Volume)
      • 7.3.1. Global Gastroparesis Drugs by: Type (Volume)
        • 7.3.1.1. Prokinetic Agents
        • 7.3.1.2. Antiemetic Agents
        • 7.3.1.3. Botulinum Toxin Injection
        • 7.3.1.4. Other
      • 7.3.2. Global Gastroparesis Drugs by: Application (Volume)
        • 7.3.2.1. Diabetic Gastroparesis
        • 7.3.2.2. Idiopathic Gastroparesis
        • 7.3.2.3. Post-Surgical Gastroparesis
      • 7.3.3. Global Gastroparesis Drugs by: End-users (Volume)
        • 7.3.3.1. Hospitals
        • 7.3.3.2. Clinics
        • 7.3.3.3. Ambulatory Surgical Centres
        • 7.3.3.4. Others
      • 7.3.4. Global Gastroparesis Drugs by: Distribution Channel (Volume)
        • 7.3.4.1. Hospital Pharmacies
        • 7.3.4.2. Retail Pharmacies
        • 7.3.4.3. Online
        • 7.3.4.4. Others
      • 7.3.5. Global Gastroparesis Drugs by: Diagnosis (Volume)
        • 7.3.5.1. Gastric Emptying Tests (Scintigraphy and Breath tests)
        • 7.3.5.2. Upper gastrointestinal (GI) endoscopy
        • 7.3.5.3. Ultrasound
      • 7.3.6. Global Gastroparesis Drugs Region
        • 7.3.6.1. South America
          • 7.3.6.1.1. Brazil
          • 7.3.6.1.2. Argentina
          • 7.3.6.1.3. Rest of South America
        • 7.3.6.2. Asia Pacific
          • 7.3.6.2.1. China
          • 7.3.6.2.2. Japan
          • 7.3.6.2.3. India
          • 7.3.6.2.4. South Korea
          • 7.3.6.2.5. Taiwan
          • 7.3.6.2.6. Australia
          • 7.3.6.2.7. Rest of Asia-Pacific
        • 7.3.6.3. Europe
          • 7.3.6.3.1. Germany
          • 7.3.6.3.2. France
          • 7.3.6.3.3. Italy
          • 7.3.6.3.4. United Kingdom
          • 7.3.6.3.5. Netherlands
          • 7.3.6.3.6. Rest of Europe
        • 7.3.6.4. MEA
          • 7.3.6.4.1. Middle East
          • 7.3.6.4.2. Africa
        • 7.3.6.5. North America
          • 7.3.6.5.1. United States
          • 7.3.6.5.2. Canada
          • 7.3.6.5.3. Mexico
    • 7.4. Global Gastroparesis Drugs (Price)
      • 7.4.1. Global Gastroparesis Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Gastroparesis Drugs: by Type(USD Million)
  • Table 2. Gastroparesis Drugs Prokinetic Agents , by Region USD Million (2018-2023)
  • Table 3. Gastroparesis Drugs Antiemetic Agents , by Region USD Million (2018-2023)
  • Table 4. Gastroparesis Drugs Botulinum Toxin Injection , by Region USD Million (2018-2023)
  • Table 5. Gastroparesis Drugs Other , by Region USD Million (2018-2023)
  • Table 6. Gastroparesis Drugs: by Application(USD Million)
  • Table 7. Gastroparesis Drugs Diabetic Gastroparesis , by Region USD Million (2018-2023)
  • Table 8. Gastroparesis Drugs Idiopathic Gastroparesis , by Region USD Million (2018-2023)
  • Table 9. Gastroparesis Drugs Post-Surgical Gastroparesis , by Region USD Million (2018-2023)
  • Table 10. Gastroparesis Drugs: by End-users(USD Million)
  • Table 11. Gastroparesis Drugs Hospitals , by Region USD Million (2018-2023)
  • Table 12. Gastroparesis Drugs Clinics , by Region USD Million (2018-2023)
  • Table 13. Gastroparesis Drugs Ambulatory Surgical Centres , by Region USD Million (2018-2023)
  • Table 14. Gastroparesis Drugs Others , by Region USD Million (2018-2023)
  • Table 15. Gastroparesis Drugs: by Distribution Channel(USD Million)
  • Table 16. Gastroparesis Drugs Hospital Pharmacies , by Region USD Million (2018-2023)
  • Table 17. Gastroparesis Drugs Retail Pharmacies , by Region USD Million (2018-2023)
  • Table 18. Gastroparesis Drugs Online , by Region USD Million (2018-2023)
  • Table 19. Gastroparesis Drugs Others , by Region USD Million (2018-2023)
  • Table 20. Gastroparesis Drugs: by Diagnosis(USD Million)
  • Table 21. Gastroparesis Drugs Gastric Emptying Tests (Scintigraphy and Breath tests) , by Region USD Million (2018-2023)
  • Table 22. Gastroparesis Drugs Upper gastrointestinal (GI) endoscopy , by Region USD Million (2018-2023)
  • Table 23. Gastroparesis Drugs Ultrasound , by Region USD Million (2018-2023)
  • Table 24. South America Gastroparesis Drugs, by Country USD Million (2018-2023)
  • Table 25. South America Gastroparesis Drugs, by Type USD Million (2018-2023)
  • Table 26. South America Gastroparesis Drugs, by Application USD Million (2018-2023)
  • Table 27. South America Gastroparesis Drugs, by End-users USD Million (2018-2023)
  • Table 28. South America Gastroparesis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 29. South America Gastroparesis Drugs, by Diagnosis USD Million (2018-2023)
  • Table 30. Brazil Gastroparesis Drugs, by Type USD Million (2018-2023)
  • Table 31. Brazil Gastroparesis Drugs, by Application USD Million (2018-2023)
  • Table 32. Brazil Gastroparesis Drugs, by End-users USD Million (2018-2023)
  • Table 33. Brazil Gastroparesis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 34. Brazil Gastroparesis Drugs, by Diagnosis USD Million (2018-2023)
  • Table 35. Argentina Gastroparesis Drugs, by Type USD Million (2018-2023)
  • Table 36. Argentina Gastroparesis Drugs, by Application USD Million (2018-2023)
  • Table 37. Argentina Gastroparesis Drugs, by End-users USD Million (2018-2023)
  • Table 38. Argentina Gastroparesis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 39. Argentina Gastroparesis Drugs, by Diagnosis USD Million (2018-2023)
  • Table 40. Rest of South America Gastroparesis Drugs, by Type USD Million (2018-2023)
  • Table 41. Rest of South America Gastroparesis Drugs, by Application USD Million (2018-2023)
  • Table 42. Rest of South America Gastroparesis Drugs, by End-users USD Million (2018-2023)
  • Table 43. Rest of South America Gastroparesis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 44. Rest of South America Gastroparesis Drugs, by Diagnosis USD Million (2018-2023)
  • Table 45. Asia Pacific Gastroparesis Drugs, by Country USD Million (2018-2023)
  • Table 46. Asia Pacific Gastroparesis Drugs, by Type USD Million (2018-2023)
  • Table 47. Asia Pacific Gastroparesis Drugs, by Application USD Million (2018-2023)
  • Table 48. Asia Pacific Gastroparesis Drugs, by End-users USD Million (2018-2023)
  • Table 49. Asia Pacific Gastroparesis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 50. Asia Pacific Gastroparesis Drugs, by Diagnosis USD Million (2018-2023)
  • Table 51. China Gastroparesis Drugs, by Type USD Million (2018-2023)
  • Table 52. China Gastroparesis Drugs, by Application USD Million (2018-2023)
  • Table 53. China Gastroparesis Drugs, by End-users USD Million (2018-2023)
  • Table 54. China Gastroparesis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 55. China Gastroparesis Drugs, by Diagnosis USD Million (2018-2023)
  • Table 56. Japan Gastroparesis Drugs, by Type USD Million (2018-2023)
  • Table 57. Japan Gastroparesis Drugs, by Application USD Million (2018-2023)
  • Table 58. Japan Gastroparesis Drugs, by End-users USD Million (2018-2023)
  • Table 59. Japan Gastroparesis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 60. Japan Gastroparesis Drugs, by Diagnosis USD Million (2018-2023)
  • Table 61. India Gastroparesis Drugs, by Type USD Million (2018-2023)
  • Table 62. India Gastroparesis Drugs, by Application USD Million (2018-2023)
  • Table 63. India Gastroparesis Drugs, by End-users USD Million (2018-2023)
  • Table 64. India Gastroparesis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 65. India Gastroparesis Drugs, by Diagnosis USD Million (2018-2023)
  • Table 66. South Korea Gastroparesis Drugs, by Type USD Million (2018-2023)
  • Table 67. South Korea Gastroparesis Drugs, by Application USD Million (2018-2023)
  • Table 68. South Korea Gastroparesis Drugs, by End-users USD Million (2018-2023)
  • Table 69. South Korea Gastroparesis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 70. South Korea Gastroparesis Drugs, by Diagnosis USD Million (2018-2023)
  • Table 71. Taiwan Gastroparesis Drugs, by Type USD Million (2018-2023)
  • Table 72. Taiwan Gastroparesis Drugs, by Application USD Million (2018-2023)
  • Table 73. Taiwan Gastroparesis Drugs, by End-users USD Million (2018-2023)
  • Table 74. Taiwan Gastroparesis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 75. Taiwan Gastroparesis Drugs, by Diagnosis USD Million (2018-2023)
  • Table 76. Australia Gastroparesis Drugs, by Type USD Million (2018-2023)
  • Table 77. Australia Gastroparesis Drugs, by Application USD Million (2018-2023)
  • Table 78. Australia Gastroparesis Drugs, by End-users USD Million (2018-2023)
  • Table 79. Australia Gastroparesis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 80. Australia Gastroparesis Drugs, by Diagnosis USD Million (2018-2023)
  • Table 81. Rest of Asia-Pacific Gastroparesis Drugs, by Type USD Million (2018-2023)
  • Table 82. Rest of Asia-Pacific Gastroparesis Drugs, by Application USD Million (2018-2023)
  • Table 83. Rest of Asia-Pacific Gastroparesis Drugs, by End-users USD Million (2018-2023)
  • Table 84. Rest of Asia-Pacific Gastroparesis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 85. Rest of Asia-Pacific Gastroparesis Drugs, by Diagnosis USD Million (2018-2023)
  • Table 86. Europe Gastroparesis Drugs, by Country USD Million (2018-2023)
  • Table 87. Europe Gastroparesis Drugs, by Type USD Million (2018-2023)
  • Table 88. Europe Gastroparesis Drugs, by Application USD Million (2018-2023)
  • Table 89. Europe Gastroparesis Drugs, by End-users USD Million (2018-2023)
  • Table 90. Europe Gastroparesis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 91. Europe Gastroparesis Drugs, by Diagnosis USD Million (2018-2023)
  • Table 92. Germany Gastroparesis Drugs, by Type USD Million (2018-2023)
  • Table 93. Germany Gastroparesis Drugs, by Application USD Million (2018-2023)
  • Table 94. Germany Gastroparesis Drugs, by End-users USD Million (2018-2023)
  • Table 95. Germany Gastroparesis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 96. Germany Gastroparesis Drugs, by Diagnosis USD Million (2018-2023)
  • Table 97. France Gastroparesis Drugs, by Type USD Million (2018-2023)
  • Table 98. France Gastroparesis Drugs, by Application USD Million (2018-2023)
  • Table 99. France Gastroparesis Drugs, by End-users USD Million (2018-2023)
  • Table 100. France Gastroparesis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 101. France Gastroparesis Drugs, by Diagnosis USD Million (2018-2023)
  • Table 102. Italy Gastroparesis Drugs, by Type USD Million (2018-2023)
  • Table 103. Italy Gastroparesis Drugs, by Application USD Million (2018-2023)
  • Table 104. Italy Gastroparesis Drugs, by End-users USD Million (2018-2023)
  • Table 105. Italy Gastroparesis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 106. Italy Gastroparesis Drugs, by Diagnosis USD Million (2018-2023)
  • Table 107. United Kingdom Gastroparesis Drugs, by Type USD Million (2018-2023)
  • Table 108. United Kingdom Gastroparesis Drugs, by Application USD Million (2018-2023)
  • Table 109. United Kingdom Gastroparesis Drugs, by End-users USD Million (2018-2023)
  • Table 110. United Kingdom Gastroparesis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 111. United Kingdom Gastroparesis Drugs, by Diagnosis USD Million (2018-2023)
  • Table 112. Netherlands Gastroparesis Drugs, by Type USD Million (2018-2023)
  • Table 113. Netherlands Gastroparesis Drugs, by Application USD Million (2018-2023)
  • Table 114. Netherlands Gastroparesis Drugs, by End-users USD Million (2018-2023)
  • Table 115. Netherlands Gastroparesis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 116. Netherlands Gastroparesis Drugs, by Diagnosis USD Million (2018-2023)
  • Table 117. Rest of Europe Gastroparesis Drugs, by Type USD Million (2018-2023)
  • Table 118. Rest of Europe Gastroparesis Drugs, by Application USD Million (2018-2023)
  • Table 119. Rest of Europe Gastroparesis Drugs, by End-users USD Million (2018-2023)
  • Table 120. Rest of Europe Gastroparesis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 121. Rest of Europe Gastroparesis Drugs, by Diagnosis USD Million (2018-2023)
  • Table 122. MEA Gastroparesis Drugs, by Country USD Million (2018-2023)
  • Table 123. MEA Gastroparesis Drugs, by Type USD Million (2018-2023)
  • Table 124. MEA Gastroparesis Drugs, by Application USD Million (2018-2023)
  • Table 125. MEA Gastroparesis Drugs, by End-users USD Million (2018-2023)
  • Table 126. MEA Gastroparesis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 127. MEA Gastroparesis Drugs, by Diagnosis USD Million (2018-2023)
  • Table 128. Middle East Gastroparesis Drugs, by Type USD Million (2018-2023)
  • Table 129. Middle East Gastroparesis Drugs, by Application USD Million (2018-2023)
  • Table 130. Middle East Gastroparesis Drugs, by End-users USD Million (2018-2023)
  • Table 131. Middle East Gastroparesis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 132. Middle East Gastroparesis Drugs, by Diagnosis USD Million (2018-2023)
  • Table 133. Africa Gastroparesis Drugs, by Type USD Million (2018-2023)
  • Table 134. Africa Gastroparesis Drugs, by Application USD Million (2018-2023)
  • Table 135. Africa Gastroparesis Drugs, by End-users USD Million (2018-2023)
  • Table 136. Africa Gastroparesis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 137. Africa Gastroparesis Drugs, by Diagnosis USD Million (2018-2023)
  • Table 138. North America Gastroparesis Drugs, by Country USD Million (2018-2023)
  • Table 139. North America Gastroparesis Drugs, by Type USD Million (2018-2023)
  • Table 140. North America Gastroparesis Drugs, by Application USD Million (2018-2023)
  • Table 141. North America Gastroparesis Drugs, by End-users USD Million (2018-2023)
  • Table 142. North America Gastroparesis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 143. North America Gastroparesis Drugs, by Diagnosis USD Million (2018-2023)
  • Table 144. United States Gastroparesis Drugs, by Type USD Million (2018-2023)
  • Table 145. United States Gastroparesis Drugs, by Application USD Million (2018-2023)
  • Table 146. United States Gastroparesis Drugs, by End-users USD Million (2018-2023)
  • Table 147. United States Gastroparesis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 148. United States Gastroparesis Drugs, by Diagnosis USD Million (2018-2023)
  • Table 149. Canada Gastroparesis Drugs, by Type USD Million (2018-2023)
  • Table 150. Canada Gastroparesis Drugs, by Application USD Million (2018-2023)
  • Table 151. Canada Gastroparesis Drugs, by End-users USD Million (2018-2023)
  • Table 152. Canada Gastroparesis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 153. Canada Gastroparesis Drugs, by Diagnosis USD Million (2018-2023)
  • Table 154. Mexico Gastroparesis Drugs, by Type USD Million (2018-2023)
  • Table 155. Mexico Gastroparesis Drugs, by Application USD Million (2018-2023)
  • Table 156. Mexico Gastroparesis Drugs, by End-users USD Million (2018-2023)
  • Table 157. Mexico Gastroparesis Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 158. Mexico Gastroparesis Drugs, by Diagnosis USD Million (2018-2023)
  • Table 159. Gastroparesis Drugs Sales: by Type(K Units)
  • Table 160. Gastroparesis Drugs Sales Prokinetic Agents , by Region K Units (2018-2023)
  • Table 161. Gastroparesis Drugs Sales Antiemetic Agents , by Region K Units (2018-2023)
  • Table 162. Gastroparesis Drugs Sales Botulinum Toxin Injection , by Region K Units (2018-2023)
  • Table 163. Gastroparesis Drugs Sales Other , by Region K Units (2018-2023)
  • Table 164. Gastroparesis Drugs Sales: by Application(K Units)
  • Table 165. Gastroparesis Drugs Sales Diabetic Gastroparesis , by Region K Units (2018-2023)
  • Table 166. Gastroparesis Drugs Sales Idiopathic Gastroparesis , by Region K Units (2018-2023)
  • Table 167. Gastroparesis Drugs Sales Post-Surgical Gastroparesis , by Region K Units (2018-2023)
  • Table 168. Gastroparesis Drugs Sales: by End-users(K Units)
  • Table 169. Gastroparesis Drugs Sales Hospitals , by Region K Units (2018-2023)
  • Table 170. Gastroparesis Drugs Sales Clinics , by Region K Units (2018-2023)
  • Table 171. Gastroparesis Drugs Sales Ambulatory Surgical Centres , by Region K Units (2018-2023)
  • Table 172. Gastroparesis Drugs Sales Others , by Region K Units (2018-2023)
  • Table 173. Gastroparesis Drugs Sales: by Distribution Channel(K Units)
  • Table 174. Gastroparesis Drugs Sales Hospital Pharmacies , by Region K Units (2018-2023)
  • Table 175. Gastroparesis Drugs Sales Retail Pharmacies , by Region K Units (2018-2023)
  • Table 176. Gastroparesis Drugs Sales Online , by Region K Units (2018-2023)
  • Table 177. Gastroparesis Drugs Sales Others , by Region K Units (2018-2023)
  • Table 178. Gastroparesis Drugs Sales: by Diagnosis(K Units)
  • Table 179. Gastroparesis Drugs Sales Gastric Emptying Tests (Scintigraphy and Breath tests) , by Region K Units (2018-2023)
  • Table 180. Gastroparesis Drugs Sales Upper gastrointestinal (GI) endoscopy , by Region K Units (2018-2023)
  • Table 181. Gastroparesis Drugs Sales Ultrasound , by Region K Units (2018-2023)
  • Table 182. South America Gastroparesis Drugs Sales, by Country K Units (2018-2023)
  • Table 183. South America Gastroparesis Drugs Sales, by Type K Units (2018-2023)
  • Table 184. South America Gastroparesis Drugs Sales, by Application K Units (2018-2023)
  • Table 185. South America Gastroparesis Drugs Sales, by End-users K Units (2018-2023)
  • Table 186. South America Gastroparesis Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 187. South America Gastroparesis Drugs Sales, by Diagnosis K Units (2018-2023)
  • Table 188. Brazil Gastroparesis Drugs Sales, by Type K Units (2018-2023)
  • Table 189. Brazil Gastroparesis Drugs Sales, by Application K Units (2018-2023)
  • Table 190. Brazil Gastroparesis Drugs Sales, by End-users K Units (2018-2023)
  • Table 191. Brazil Gastroparesis Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 192. Brazil Gastroparesis Drugs Sales, by Diagnosis K Units (2018-2023)
  • Table 193. Argentina Gastroparesis Drugs Sales, by Type K Units (2018-2023)
  • Table 194. Argentina Gastroparesis Drugs Sales, by Application K Units (2018-2023)
  • Table 195. Argentina Gastroparesis Drugs Sales, by End-users K Units (2018-2023)
  • Table 196. Argentina Gastroparesis Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 197. Argentina Gastroparesis Drugs Sales, by Diagnosis K Units (2018-2023)
  • Table 198. Rest of South America Gastroparesis Drugs Sales, by Type K Units (2018-2023)
  • Table 199. Rest of South America Gastroparesis Drugs Sales, by Application K Units (2018-2023)
  • Table 200. Rest of South America Gastroparesis Drugs Sales, by End-users K Units (2018-2023)
  • Table 201. Rest of South America Gastroparesis Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 202. Rest of South America Gastroparesis Drugs Sales, by Diagnosis K Units (2018-2023)
  • Table 203. Asia Pacific Gastroparesis Drugs Sales, by Country K Units (2018-2023)
  • Table 204. Asia Pacific Gastroparesis Drugs Sales, by Type K Units (2018-2023)
  • Table 205. Asia Pacific Gastroparesis Drugs Sales, by Application K Units (2018-2023)
  • Table 206. Asia Pacific Gastroparesis Drugs Sales, by End-users K Units (2018-2023)
  • Table 207. Asia Pacific Gastroparesis Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 208. Asia Pacific Gastroparesis Drugs Sales, by Diagnosis K Units (2018-2023)
  • Table 209. China Gastroparesis Drugs Sales, by Type K Units (2018-2023)
  • Table 210. China Gastroparesis Drugs Sales, by Application K Units (2018-2023)
  • Table 211. China Gastroparesis Drugs Sales, by End-users K Units (2018-2023)
  • Table 212. China Gastroparesis Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 213. China Gastroparesis Drugs Sales, by Diagnosis K Units (2018-2023)
  • Table 214. Japan Gastroparesis Drugs Sales, by Type K Units (2018-2023)
  • Table 215. Japan Gastroparesis Drugs Sales, by Application K Units (2018-2023)
  • Table 216. Japan Gastroparesis Drugs Sales, by End-users K Units (2018-2023)
  • Table 217. Japan Gastroparesis Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 218. Japan Gastroparesis Drugs Sales, by Diagnosis K Units (2018-2023)
  • Table 219. India Gastroparesis Drugs Sales, by Type K Units (2018-2023)
  • Table 220. India Gastroparesis Drugs Sales, by Application K Units (2018-2023)
  • Table 221. India Gastroparesis Drugs Sales, by End-users K Units (2018-2023)
  • Table 222. India Gastroparesis Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 223. India Gastroparesis Drugs Sales, by Diagnosis K Units (2018-2023)
  • Table 224. South Korea Gastroparesis Drugs Sales, by Type K Units (2018-2023)
  • Table 225. South Korea Gastroparesis Drugs Sales, by Application K Units (2018-2023)
  • Table 226. South Korea Gastroparesis Drugs Sales, by End-users K Units (2018-2023)
  • Table 227. South Korea Gastroparesis Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 228. South Korea Gastroparesis Drugs Sales, by Diagnosis K Units (2018-2023)
  • Table 229. Taiwan Gastroparesis Drugs Sales, by Type K Units (2018-2023)
  • Table 230. Taiwan Gastroparesis Drugs Sales, by Application K Units (2018-2023)
  • Table 231. Taiwan Gastroparesis Drugs Sales, by End-users K Units (2018-2023)
  • Table 232. Taiwan Gastroparesis Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 233. Taiwan Gastroparesis Drugs Sales, by Diagnosis K Units (2018-2023)
  • Table 234. Australia Gastroparesis Drugs Sales, by Type K Units (2018-2023)
  • Table 235. Australia Gastroparesis Drugs Sales, by Application K Units (2018-2023)
  • Table 236. Australia Gastroparesis Drugs Sales, by End-users K Units (2018-2023)
  • Table 237. Australia Gastroparesis Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 238. Australia Gastroparesis Drugs Sales, by Diagnosis K Units (2018-2023)
  • Table 239. Rest of Asia-Pacific Gastroparesis Drugs Sales, by Type K Units (2018-2023)
  • Table 240. Rest of Asia-Pacific Gastroparesis Drugs Sales, by Application K Units (2018-2023)
  • Table 241. Rest of Asia-Pacific Gastroparesis Drugs Sales, by End-users K Units (2018-2023)
  • Table 242. Rest of Asia-Pacific Gastroparesis Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 243. Rest of Asia-Pacific Gastroparesis Drugs Sales, by Diagnosis K Units (2018-2023)
  • Table 244. Europe Gastroparesis Drugs Sales, by Country K Units (2018-2023)
  • Table 245. Europe Gastroparesis Drugs Sales, by Type K Units (2018-2023)
  • Table 246. Europe Gastroparesis Drugs Sales, by Application K Units (2018-2023)
  • Table 247. Europe Gastroparesis Drugs Sales, by End-users K Units (2018-2023)
  • Table 248. Europe Gastroparesis Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 249. Europe Gastroparesis Drugs Sales, by Diagnosis K Units (2018-2023)
  • Table 250. Germany Gastroparesis Drugs Sales, by Type K Units (2018-2023)
  • Table 251. Germany Gastroparesis Drugs Sales, by Application K Units (2018-2023)
  • Table 252. Germany Gastroparesis Drugs Sales, by End-users K Units (2018-2023)
  • Table 253. Germany Gastroparesis Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 254. Germany Gastroparesis Drugs Sales, by Diagnosis K Units (2018-2023)
  • Table 255. France Gastroparesis Drugs Sales, by Type K Units (2018-2023)
  • Table 256. France Gastroparesis Drugs Sales, by Application K Units (2018-2023)
  • Table 257. France Gastroparesis Drugs Sales, by End-users K Units (2018-2023)
  • Table 258. France Gastroparesis Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 259. France Gastroparesis Drugs Sales, by Diagnosis K Units (2018-2023)
  • Table 260. Italy Gastroparesis Drugs Sales, by Type K Units (2018-2023)
  • Table 261. Italy Gastroparesis Drugs Sales, by Application K Units (2018-2023)
  • Table 262. Italy Gastroparesis Drugs Sales, by End-users K Units (2018-2023)
  • Table 263. Italy Gastroparesis Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 264. Italy Gastroparesis Drugs Sales, by Diagnosis K Units (2018-2023)
  • Table 265. United Kingdom Gastroparesis Drugs Sales, by Type K Units (2018-2023)
  • Table 266. United Kingdom Gastroparesis Drugs Sales, by Application K Units (2018-2023)
  • Table 267. United Kingdom Gastroparesis Drugs Sales, by End-users K Units (2018-2023)
  • Table 268. United Kingdom Gastroparesis Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 269. United Kingdom Gastroparesis Drugs Sales, by Diagnosis K Units (2018-2023)
  • Table 270. Netherlands Gastroparesis Drugs Sales, by Type K Units (2018-2023)
  • Table 271. Netherlands Gastroparesis Drugs Sales, by Application K Units (2018-2023)
  • Table 272. Netherlands Gastroparesis Drugs Sales, by End-users K Units (2018-2023)
  • Table 273. Netherlands Gastroparesis Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 274. Netherlands Gastroparesis Drugs Sales, by Diagnosis K Units (2018-2023)
  • Table 275. Rest of Europe Gastroparesis Drugs Sales, by Type K Units (2018-2023)
  • Table 276. Rest of Europe Gastroparesis Drugs Sales, by Application K Units (2018-2023)
  • Table 277. Rest of Europe Gastroparesis Drugs Sales, by End-users K Units (2018-2023)
  • Table 278. Rest of Europe Gastroparesis Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 279. Rest of Europe Gastroparesis Drugs Sales, by Diagnosis K Units (2018-2023)
  • Table 280. MEA Gastroparesis Drugs Sales, by Country K Units (2018-2023)
  • Table 281. MEA Gastroparesis Drugs Sales, by Type K Units (2018-2023)
  • Table 282. MEA Gastroparesis Drugs Sales, by Application K Units (2018-2023)
  • Table 283. MEA Gastroparesis Drugs Sales, by End-users K Units (2018-2023)
  • Table 284. MEA Gastroparesis Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 285. MEA Gastroparesis Drugs Sales, by Diagnosis K Units (2018-2023)
  • Table 286. Middle East Gastroparesis Drugs Sales, by Type K Units (2018-2023)
  • Table 287. Middle East Gastroparesis Drugs Sales, by Application K Units (2018-2023)
  • Table 288. Middle East Gastroparesis Drugs Sales, by End-users K Units (2018-2023)
  • Table 289. Middle East Gastroparesis Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 290. Middle East Gastroparesis Drugs Sales, by Diagnosis K Units (2018-2023)
  • Table 291. Africa Gastroparesis Drugs Sales, by Type K Units (2018-2023)
  • Table 292. Africa Gastroparesis Drugs Sales, by Application K Units (2018-2023)
  • Table 293. Africa Gastroparesis Drugs Sales, by End-users K Units (2018-2023)
  • Table 294. Africa Gastroparesis Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 295. Africa Gastroparesis Drugs Sales, by Diagnosis K Units (2018-2023)
  • Table 296. North America Gastroparesis Drugs Sales, by Country K Units (2018-2023)
  • Table 297. North America Gastroparesis Drugs Sales, by Type K Units (2018-2023)
  • Table 298. North America Gastroparesis Drugs Sales, by Application K Units (2018-2023)
  • Table 299. North America Gastroparesis Drugs Sales, by End-users K Units (2018-2023)
  • Table 300. North America Gastroparesis Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 301. North America Gastroparesis Drugs Sales, by Diagnosis K Units (2018-2023)
  • Table 302. United States Gastroparesis Drugs Sales, by Type K Units (2018-2023)
  • Table 303. United States Gastroparesis Drugs Sales, by Application K Units (2018-2023)
  • Table 304. United States Gastroparesis Drugs Sales, by End-users K Units (2018-2023)
  • Table 305. United States Gastroparesis Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 306. United States Gastroparesis Drugs Sales, by Diagnosis K Units (2018-2023)
  • Table 307. Canada Gastroparesis Drugs Sales, by Type K Units (2018-2023)
  • Table 308. Canada Gastroparesis Drugs Sales, by Application K Units (2018-2023)
  • Table 309. Canada Gastroparesis Drugs Sales, by End-users K Units (2018-2023)
  • Table 310. Canada Gastroparesis Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 311. Canada Gastroparesis Drugs Sales, by Diagnosis K Units (2018-2023)
  • Table 312. Mexico Gastroparesis Drugs Sales, by Type K Units (2018-2023)
  • Table 313. Mexico Gastroparesis Drugs Sales, by Application K Units (2018-2023)
  • Table 314. Mexico Gastroparesis Drugs Sales, by End-users K Units (2018-2023)
  • Table 315. Mexico Gastroparesis Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 316. Mexico Gastroparesis Drugs Sales, by Diagnosis K Units (2018-2023)
  • Table 317. Gastroparesis Drugs: by Type(USD/Units)
  • Table 318. Company Basic Information, Sales Area and Its Competitors
  • Table 319. Company Basic Information, Sales Area and Its Competitors
  • Table 320. Company Basic Information, Sales Area and Its Competitors
  • Table 321. Company Basic Information, Sales Area and Its Competitors
  • Table 322. Company Basic Information, Sales Area and Its Competitors
  • Table 323. Company Basic Information, Sales Area and Its Competitors
  • Table 324. Company Basic Information, Sales Area and Its Competitors
  • Table 325. Company Basic Information, Sales Area and Its Competitors
  • Table 326. Company Basic Information, Sales Area and Its Competitors
  • Table 327. Gastroparesis Drugs: by Type(USD Million)
  • Table 328. Gastroparesis Drugs Prokinetic Agents , by Region USD Million (2025-2030)
  • Table 329. Gastroparesis Drugs Antiemetic Agents , by Region USD Million (2025-2030)
  • Table 330. Gastroparesis Drugs Botulinum Toxin Injection , by Region USD Million (2025-2030)
  • Table 331. Gastroparesis Drugs Other , by Region USD Million (2025-2030)
  • Table 332. Gastroparesis Drugs: by Application(USD Million)
  • Table 333. Gastroparesis Drugs Diabetic Gastroparesis , by Region USD Million (2025-2030)
  • Table 334. Gastroparesis Drugs Idiopathic Gastroparesis , by Region USD Million (2025-2030)
  • Table 335. Gastroparesis Drugs Post-Surgical Gastroparesis , by Region USD Million (2025-2030)
  • Table 336. Gastroparesis Drugs: by End-users(USD Million)
  • Table 337. Gastroparesis Drugs Hospitals , by Region USD Million (2025-2030)
  • Table 338. Gastroparesis Drugs Clinics , by Region USD Million (2025-2030)
  • Table 339. Gastroparesis Drugs Ambulatory Surgical Centres , by Region USD Million (2025-2030)
  • Table 340. Gastroparesis Drugs Others , by Region USD Million (2025-2030)
  • Table 341. Gastroparesis Drugs: by Distribution Channel(USD Million)
  • Table 342. Gastroparesis Drugs Hospital Pharmacies , by Region USD Million (2025-2030)
  • Table 343. Gastroparesis Drugs Retail Pharmacies , by Region USD Million (2025-2030)
  • Table 344. Gastroparesis Drugs Online , by Region USD Million (2025-2030)
  • Table 345. Gastroparesis Drugs Others , by Region USD Million (2025-2030)
  • Table 346. Gastroparesis Drugs: by Diagnosis(USD Million)
  • Table 347. Gastroparesis Drugs Gastric Emptying Tests (Scintigraphy and Breath tests) , by Region USD Million (2025-2030)
  • Table 348. Gastroparesis Drugs Upper gastrointestinal (GI) endoscopy , by Region USD Million (2025-2030)
  • Table 349. Gastroparesis Drugs Ultrasound , by Region USD Million (2025-2030)
  • Table 350. South America Gastroparesis Drugs, by Country USD Million (2025-2030)
  • Table 351. South America Gastroparesis Drugs, by Type USD Million (2025-2030)
  • Table 352. South America Gastroparesis Drugs, by Application USD Million (2025-2030)
  • Table 353. South America Gastroparesis Drugs, by End-users USD Million (2025-2030)
  • Table 354. South America Gastroparesis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 355. South America Gastroparesis Drugs, by Diagnosis USD Million (2025-2030)
  • Table 356. Brazil Gastroparesis Drugs, by Type USD Million (2025-2030)
  • Table 357. Brazil Gastroparesis Drugs, by Application USD Million (2025-2030)
  • Table 358. Brazil Gastroparesis Drugs, by End-users USD Million (2025-2030)
  • Table 359. Brazil Gastroparesis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 360. Brazil Gastroparesis Drugs, by Diagnosis USD Million (2025-2030)
  • Table 361. Argentina Gastroparesis Drugs, by Type USD Million (2025-2030)
  • Table 362. Argentina Gastroparesis Drugs, by Application USD Million (2025-2030)
  • Table 363. Argentina Gastroparesis Drugs, by End-users USD Million (2025-2030)
  • Table 364. Argentina Gastroparesis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 365. Argentina Gastroparesis Drugs, by Diagnosis USD Million (2025-2030)
  • Table 366. Rest of South America Gastroparesis Drugs, by Type USD Million (2025-2030)
  • Table 367. Rest of South America Gastroparesis Drugs, by Application USD Million (2025-2030)
  • Table 368. Rest of South America Gastroparesis Drugs, by End-users USD Million (2025-2030)
  • Table 369. Rest of South America Gastroparesis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 370. Rest of South America Gastroparesis Drugs, by Diagnosis USD Million (2025-2030)
  • Table 371. Asia Pacific Gastroparesis Drugs, by Country USD Million (2025-2030)
  • Table 372. Asia Pacific Gastroparesis Drugs, by Type USD Million (2025-2030)
  • Table 373. Asia Pacific Gastroparesis Drugs, by Application USD Million (2025-2030)
  • Table 374. Asia Pacific Gastroparesis Drugs, by End-users USD Million (2025-2030)
  • Table 375. Asia Pacific Gastroparesis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 376. Asia Pacific Gastroparesis Drugs, by Diagnosis USD Million (2025-2030)
  • Table 377. China Gastroparesis Drugs, by Type USD Million (2025-2030)
  • Table 378. China Gastroparesis Drugs, by Application USD Million (2025-2030)
  • Table 379. China Gastroparesis Drugs, by End-users USD Million (2025-2030)
  • Table 380. China Gastroparesis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 381. China Gastroparesis Drugs, by Diagnosis USD Million (2025-2030)
  • Table 382. Japan Gastroparesis Drugs, by Type USD Million (2025-2030)
  • Table 383. Japan Gastroparesis Drugs, by Application USD Million (2025-2030)
  • Table 384. Japan Gastroparesis Drugs, by End-users USD Million (2025-2030)
  • Table 385. Japan Gastroparesis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 386. Japan Gastroparesis Drugs, by Diagnosis USD Million (2025-2030)
  • Table 387. India Gastroparesis Drugs, by Type USD Million (2025-2030)
  • Table 388. India Gastroparesis Drugs, by Application USD Million (2025-2030)
  • Table 389. India Gastroparesis Drugs, by End-users USD Million (2025-2030)
  • Table 390. India Gastroparesis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 391. India Gastroparesis Drugs, by Diagnosis USD Million (2025-2030)
  • Table 392. South Korea Gastroparesis Drugs, by Type USD Million (2025-2030)
  • Table 393. South Korea Gastroparesis Drugs, by Application USD Million (2025-2030)
  • Table 394. South Korea Gastroparesis Drugs, by End-users USD Million (2025-2030)
  • Table 395. South Korea Gastroparesis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 396. South Korea Gastroparesis Drugs, by Diagnosis USD Million (2025-2030)
  • Table 397. Taiwan Gastroparesis Drugs, by Type USD Million (2025-2030)
  • Table 398. Taiwan Gastroparesis Drugs, by Application USD Million (2025-2030)
  • Table 399. Taiwan Gastroparesis Drugs, by End-users USD Million (2025-2030)
  • Table 400. Taiwan Gastroparesis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 401. Taiwan Gastroparesis Drugs, by Diagnosis USD Million (2025-2030)
  • Table 402. Australia Gastroparesis Drugs, by Type USD Million (2025-2030)
  • Table 403. Australia Gastroparesis Drugs, by Application USD Million (2025-2030)
  • Table 404. Australia Gastroparesis Drugs, by End-users USD Million (2025-2030)
  • Table 405. Australia Gastroparesis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 406. Australia Gastroparesis Drugs, by Diagnosis USD Million (2025-2030)
  • Table 407. Rest of Asia-Pacific Gastroparesis Drugs, by Type USD Million (2025-2030)
  • Table 408. Rest of Asia-Pacific Gastroparesis Drugs, by Application USD Million (2025-2030)
  • Table 409. Rest of Asia-Pacific Gastroparesis Drugs, by End-users USD Million (2025-2030)
  • Table 410. Rest of Asia-Pacific Gastroparesis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 411. Rest of Asia-Pacific Gastroparesis Drugs, by Diagnosis USD Million (2025-2030)
  • Table 412. Europe Gastroparesis Drugs, by Country USD Million (2025-2030)
  • Table 413. Europe Gastroparesis Drugs, by Type USD Million (2025-2030)
  • Table 414. Europe Gastroparesis Drugs, by Application USD Million (2025-2030)
  • Table 415. Europe Gastroparesis Drugs, by End-users USD Million (2025-2030)
  • Table 416. Europe Gastroparesis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 417. Europe Gastroparesis Drugs, by Diagnosis USD Million (2025-2030)
  • Table 418. Germany Gastroparesis Drugs, by Type USD Million (2025-2030)
  • Table 419. Germany Gastroparesis Drugs, by Application USD Million (2025-2030)
  • Table 420. Germany Gastroparesis Drugs, by End-users USD Million (2025-2030)
  • Table 421. Germany Gastroparesis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 422. Germany Gastroparesis Drugs, by Diagnosis USD Million (2025-2030)
  • Table 423. France Gastroparesis Drugs, by Type USD Million (2025-2030)
  • Table 424. France Gastroparesis Drugs, by Application USD Million (2025-2030)
  • Table 425. France Gastroparesis Drugs, by End-users USD Million (2025-2030)
  • Table 426. France Gastroparesis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 427. France Gastroparesis Drugs, by Diagnosis USD Million (2025-2030)
  • Table 428. Italy Gastroparesis Drugs, by Type USD Million (2025-2030)
  • Table 429. Italy Gastroparesis Drugs, by Application USD Million (2025-2030)
  • Table 430. Italy Gastroparesis Drugs, by End-users USD Million (2025-2030)
  • Table 431. Italy Gastroparesis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 432. Italy Gastroparesis Drugs, by Diagnosis USD Million (2025-2030)
  • Table 433. United Kingdom Gastroparesis Drugs, by Type USD Million (2025-2030)
  • Table 434. United Kingdom Gastroparesis Drugs, by Application USD Million (2025-2030)
  • Table 435. United Kingdom Gastroparesis Drugs, by End-users USD Million (2025-2030)
  • Table 436. United Kingdom Gastroparesis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 437. United Kingdom Gastroparesis Drugs, by Diagnosis USD Million (2025-2030)
  • Table 438. Netherlands Gastroparesis Drugs, by Type USD Million (2025-2030)
  • Table 439. Netherlands Gastroparesis Drugs, by Application USD Million (2025-2030)
  • Table 440. Netherlands Gastroparesis Drugs, by End-users USD Million (2025-2030)
  • Table 441. Netherlands Gastroparesis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 442. Netherlands Gastroparesis Drugs, by Diagnosis USD Million (2025-2030)
  • Table 443. Rest of Europe Gastroparesis Drugs, by Type USD Million (2025-2030)
  • Table 444. Rest of Europe Gastroparesis Drugs, by Application USD Million (2025-2030)
  • Table 445. Rest of Europe Gastroparesis Drugs, by End-users USD Million (2025-2030)
  • Table 446. Rest of Europe Gastroparesis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 447. Rest of Europe Gastroparesis Drugs, by Diagnosis USD Million (2025-2030)
  • Table 448. MEA Gastroparesis Drugs, by Country USD Million (2025-2030)
  • Table 449. MEA Gastroparesis Drugs, by Type USD Million (2025-2030)
  • Table 450. MEA Gastroparesis Drugs, by Application USD Million (2025-2030)
  • Table 451. MEA Gastroparesis Drugs, by End-users USD Million (2025-2030)
  • Table 452. MEA Gastroparesis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 453. MEA Gastroparesis Drugs, by Diagnosis USD Million (2025-2030)
  • Table 454. Middle East Gastroparesis Drugs, by Type USD Million (2025-2030)
  • Table 455. Middle East Gastroparesis Drugs, by Application USD Million (2025-2030)
  • Table 456. Middle East Gastroparesis Drugs, by End-users USD Million (2025-2030)
  • Table 457. Middle East Gastroparesis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 458. Middle East Gastroparesis Drugs, by Diagnosis USD Million (2025-2030)
  • Table 459. Africa Gastroparesis Drugs, by Type USD Million (2025-2030)
  • Table 460. Africa Gastroparesis Drugs, by Application USD Million (2025-2030)
  • Table 461. Africa Gastroparesis Drugs, by End-users USD Million (2025-2030)
  • Table 462. Africa Gastroparesis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 463. Africa Gastroparesis Drugs, by Diagnosis USD Million (2025-2030)
  • Table 464. North America Gastroparesis Drugs, by Country USD Million (2025-2030)
  • Table 465. North America Gastroparesis Drugs, by Type USD Million (2025-2030)
  • Table 466. North America Gastroparesis Drugs, by Application USD Million (2025-2030)
  • Table 467. North America Gastroparesis Drugs, by End-users USD Million (2025-2030)
  • Table 468. North America Gastroparesis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 469. North America Gastroparesis Drugs, by Diagnosis USD Million (2025-2030)
  • Table 470. United States Gastroparesis Drugs, by Type USD Million (2025-2030)
  • Table 471. United States Gastroparesis Drugs, by Application USD Million (2025-2030)
  • Table 472. United States Gastroparesis Drugs, by End-users USD Million (2025-2030)
  • Table 473. United States Gastroparesis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 474. United States Gastroparesis Drugs, by Diagnosis USD Million (2025-2030)
  • Table 475. Canada Gastroparesis Drugs, by Type USD Million (2025-2030)
  • Table 476. Canada Gastroparesis Drugs, by Application USD Million (2025-2030)
  • Table 477. Canada Gastroparesis Drugs, by End-users USD Million (2025-2030)
  • Table 478. Canada Gastroparesis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 479. Canada Gastroparesis Drugs, by Diagnosis USD Million (2025-2030)
  • Table 480. Mexico Gastroparesis Drugs, by Type USD Million (2025-2030)
  • Table 481. Mexico Gastroparesis Drugs, by Application USD Million (2025-2030)
  • Table 482. Mexico Gastroparesis Drugs, by End-users USD Million (2025-2030)
  • Table 483. Mexico Gastroparesis Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 484. Mexico Gastroparesis Drugs, by Diagnosis USD Million (2025-2030)
  • Table 485. Gastroparesis Drugs Sales: by Type(K Units)
  • Table 486. Gastroparesis Drugs Sales Prokinetic Agents , by Region K Units (2025-2030)
  • Table 487. Gastroparesis Drugs Sales Antiemetic Agents , by Region K Units (2025-2030)
  • Table 488. Gastroparesis Drugs Sales Botulinum Toxin Injection , by Region K Units (2025-2030)
  • Table 489. Gastroparesis Drugs Sales Other , by Region K Units (2025-2030)
  • Table 490. Gastroparesis Drugs Sales: by Application(K Units)
  • Table 491. Gastroparesis Drugs Sales Diabetic Gastroparesis , by Region K Units (2025-2030)
  • Table 492. Gastroparesis Drugs Sales Idiopathic Gastroparesis , by Region K Units (2025-2030)
  • Table 493. Gastroparesis Drugs Sales Post-Surgical Gastroparesis , by Region K Units (2025-2030)
  • Table 494. Gastroparesis Drugs Sales: by End-users(K Units)
  • Table 495. Gastroparesis Drugs Sales Hospitals , by Region K Units (2025-2030)
  • Table 496. Gastroparesis Drugs Sales Clinics , by Region K Units (2025-2030)
  • Table 497. Gastroparesis Drugs Sales Ambulatory Surgical Centres , by Region K Units (2025-2030)
  • Table 498. Gastroparesis Drugs Sales Others , by Region K Units (2025-2030)
  • Table 499. Gastroparesis Drugs Sales: by Distribution Channel(K Units)
  • Table 500. Gastroparesis Drugs Sales Hospital Pharmacies , by Region K Units (2025-2030)
  • Table 501. Gastroparesis Drugs Sales Retail Pharmacies , by Region K Units (2025-2030)
  • Table 502. Gastroparesis Drugs Sales Online , by Region K Units (2025-2030)
  • Table 503. Gastroparesis Drugs Sales Others , by Region K Units (2025-2030)
  • Table 504. Gastroparesis Drugs Sales: by Diagnosis(K Units)
  • Table 505. Gastroparesis Drugs Sales Gastric Emptying Tests (Scintigraphy and Breath tests) , by Region K Units (2025-2030)
  • Table 506. Gastroparesis Drugs Sales Upper gastrointestinal (GI) endoscopy , by Region K Units (2025-2030)
  • Table 507. Gastroparesis Drugs Sales Ultrasound , by Region K Units (2025-2030)
  • Table 508. South America Gastroparesis Drugs Sales, by Country K Units (2025-2030)
  • Table 509. South America Gastroparesis Drugs Sales, by Type K Units (2025-2030)
  • Table 510. South America Gastroparesis Drugs Sales, by Application K Units (2025-2030)
  • Table 511. South America Gastroparesis Drugs Sales, by End-users K Units (2025-2030)
  • Table 512. South America Gastroparesis Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 513. South America Gastroparesis Drugs Sales, by Diagnosis K Units (2025-2030)
  • Table 514. Brazil Gastroparesis Drugs Sales, by Type K Units (2025-2030)
  • Table 515. Brazil Gastroparesis Drugs Sales, by Application K Units (2025-2030)
  • Table 516. Brazil Gastroparesis Drugs Sales, by End-users K Units (2025-2030)
  • Table 517. Brazil Gastroparesis Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 518. Brazil Gastroparesis Drugs Sales, by Diagnosis K Units (2025-2030)
  • Table 519. Argentina Gastroparesis Drugs Sales, by Type K Units (2025-2030)
  • Table 520. Argentina Gastroparesis Drugs Sales, by Application K Units (2025-2030)
  • Table 521. Argentina Gastroparesis Drugs Sales, by End-users K Units (2025-2030)
  • Table 522. Argentina Gastroparesis Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 523. Argentina Gastroparesis Drugs Sales, by Diagnosis K Units (2025-2030)
  • Table 524. Rest of South America Gastroparesis Drugs Sales, by Type K Units (2025-2030)
  • Table 525. Rest of South America Gastroparesis Drugs Sales, by Application K Units (2025-2030)
  • Table 526. Rest of South America Gastroparesis Drugs Sales, by End-users K Units (2025-2030)
  • Table 527. Rest of South America Gastroparesis Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 528. Rest of South America Gastroparesis Drugs Sales, by Diagnosis K Units (2025-2030)
  • Table 529. Asia Pacific Gastroparesis Drugs Sales, by Country K Units (2025-2030)
  • Table 530. Asia Pacific Gastroparesis Drugs Sales, by Type K Units (2025-2030)
  • Table 531. Asia Pacific Gastroparesis Drugs Sales, by Application K Units (2025-2030)
  • Table 532. Asia Pacific Gastroparesis Drugs Sales, by End-users K Units (2025-2030)
  • Table 533. Asia Pacific Gastroparesis Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 534. Asia Pacific Gastroparesis Drugs Sales, by Diagnosis K Units (2025-2030)
  • Table 535. China Gastroparesis Drugs Sales, by Type K Units (2025-2030)
  • Table 536. China Gastroparesis Drugs Sales, by Application K Units (2025-2030)
  • Table 537. China Gastroparesis Drugs Sales, by End-users K Units (2025-2030)
  • Table 538. China Gastroparesis Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 539. China Gastroparesis Drugs Sales, by Diagnosis K Units (2025-2030)
  • Table 540. Japan Gastroparesis Drugs Sales, by Type K Units (2025-2030)
  • Table 541. Japan Gastroparesis Drugs Sales, by Application K Units (2025-2030)
  • Table 542. Japan Gastroparesis Drugs Sales, by End-users K Units (2025-2030)
  • Table 543. Japan Gastroparesis Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 544. Japan Gastroparesis Drugs Sales, by Diagnosis K Units (2025-2030)
  • Table 545. India Gastroparesis Drugs Sales, by Type K Units (2025-2030)
  • Table 546. India Gastroparesis Drugs Sales, by Application K Units (2025-2030)
  • Table 547. India Gastroparesis Drugs Sales, by End-users K Units (2025-2030)
  • Table 548. India Gastroparesis Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 549. India Gastroparesis Drugs Sales, by Diagnosis K Units (2025-2030)
  • Table 550. South Korea Gastroparesis Drugs Sales, by Type K Units (2025-2030)
  • Table 551. South Korea Gastroparesis Drugs Sales, by Application K Units (2025-2030)
  • Table 552. South Korea Gastroparesis Drugs Sales, by End-users K Units (2025-2030)
  • Table 553. South Korea Gastroparesis Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 554. South Korea Gastroparesis Drugs Sales, by Diagnosis K Units (2025-2030)
  • Table 555. Taiwan Gastroparesis Drugs Sales, by Type K Units (2025-2030)
  • Table 556. Taiwan Gastroparesis Drugs Sales, by Application K Units (2025-2030)
  • Table 557. Taiwan Gastroparesis Drugs Sales, by End-users K Units (2025-2030)
  • Table 558. Taiwan Gastroparesis Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 559. Taiwan Gastroparesis Drugs Sales, by Diagnosis K Units (2025-2030)
  • Table 560. Australia Gastroparesis Drugs Sales, by Type K Units (2025-2030)
  • Table 561. Australia Gastroparesis Drugs Sales, by Application K Units (2025-2030)
  • Table 562. Australia Gastroparesis Drugs Sales, by End-users K Units (2025-2030)
  • Table 563. Australia Gastroparesis Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 564. Australia Gastroparesis Drugs Sales, by Diagnosis K Units (2025-2030)
  • Table 565. Rest of Asia-Pacific Gastroparesis Drugs Sales, by Type K Units (2025-2030)
  • Table 566. Rest of Asia-Pacific Gastroparesis Drugs Sales, by Application K Units (2025-2030)
  • Table 567. Rest of Asia-Pacific Gastroparesis Drugs Sales, by End-users K Units (2025-2030)
  • Table 568. Rest of Asia-Pacific Gastroparesis Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 569. Rest of Asia-Pacific Gastroparesis Drugs Sales, by Diagnosis K Units (2025-2030)
  • Table 570. Europe Gastroparesis Drugs Sales, by Country K Units (2025-2030)
  • Table 571. Europe Gastroparesis Drugs Sales, by Type K Units (2025-2030)
  • Table 572. Europe Gastroparesis Drugs Sales, by Application K Units (2025-2030)
  • Table 573. Europe Gastroparesis Drugs Sales, by End-users K Units (2025-2030)
  • Table 574. Europe Gastroparesis Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 575. Europe Gastroparesis Drugs Sales, by Diagnosis K Units (2025-2030)
  • Table 576. Germany Gastroparesis Drugs Sales, by Type K Units (2025-2030)
  • Table 577. Germany Gastroparesis Drugs Sales, by Application K Units (2025-2030)
  • Table 578. Germany Gastroparesis Drugs Sales, by End-users K Units (2025-2030)
  • Table 579. Germany Gastroparesis Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 580. Germany Gastroparesis Drugs Sales, by Diagnosis K Units (2025-2030)
  • Table 581. France Gastroparesis Drugs Sales, by Type K Units (2025-2030)
  • Table 582. France Gastroparesis Drugs Sales, by Application K Units (2025-2030)
  • Table 583. France Gastroparesis Drugs Sales, by End-users K Units (2025-2030)
  • Table 584. France Gastroparesis Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 585. France Gastroparesis Drugs Sales, by Diagnosis K Units (2025-2030)
  • Table 586. Italy Gastroparesis Drugs Sales, by Type K Units (2025-2030)
  • Table 587. Italy Gastroparesis Drugs Sales, by Application K Units (2025-2030)
  • Table 588. Italy Gastroparesis Drugs Sales, by End-users K Units (2025-2030)
  • Table 589. Italy Gastroparesis Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 590. Italy Gastroparesis Drugs Sales, by Diagnosis K Units (2025-2030)
  • Table 591. United Kingdom Gastroparesis Drugs Sales, by Type K Units (2025-2030)
  • Table 592. United Kingdom Gastroparesis Drugs Sales, by Application K Units (2025-2030)
  • Table 593. United Kingdom Gastroparesis Drugs Sales, by End-users K Units (2025-2030)
  • Table 594. United Kingdom Gastroparesis Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 595. United Kingdom Gastroparesis Drugs Sales, by Diagnosis K Units (2025-2030)
  • Table 596. Netherlands Gastroparesis Drugs Sales, by Type K Units (2025-2030)
  • Table 597. Netherlands Gastroparesis Drugs Sales, by Application K Units (2025-2030)
  • Table 598. Netherlands Gastroparesis Drugs Sales, by End-users K Units (2025-2030)
  • Table 599. Netherlands Gastroparesis Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 600. Netherlands Gastroparesis Drugs Sales, by Diagnosis K Units (2025-2030)
  • Table 601. Rest of Europe Gastroparesis Drugs Sales, by Type K Units (2025-2030)
  • Table 602. Rest of Europe Gastroparesis Drugs Sales, by Application K Units (2025-2030)
  • Table 603. Rest of Europe Gastroparesis Drugs Sales, by End-users K Units (2025-2030)
  • Table 604. Rest of Europe Gastroparesis Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 605. Rest of Europe Gastroparesis Drugs Sales, by Diagnosis K Units (2025-2030)
  • Table 606. MEA Gastroparesis Drugs Sales, by Country K Units (2025-2030)
  • Table 607. MEA Gastroparesis Drugs Sales, by Type K Units (2025-2030)
  • Table 608. MEA Gastroparesis Drugs Sales, by Application K Units (2025-2030)
  • Table 609. MEA Gastroparesis Drugs Sales, by End-users K Units (2025-2030)
  • Table 610. MEA Gastroparesis Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 611. MEA Gastroparesis Drugs Sales, by Diagnosis K Units (2025-2030)
  • Table 612. Middle East Gastroparesis Drugs Sales, by Type K Units (2025-2030)
  • Table 613. Middle East Gastroparesis Drugs Sales, by Application K Units (2025-2030)
  • Table 614. Middle East Gastroparesis Drugs Sales, by End-users K Units (2025-2030)
  • Table 615. Middle East Gastroparesis Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 616. Middle East Gastroparesis Drugs Sales, by Diagnosis K Units (2025-2030)
  • Table 617. Africa Gastroparesis Drugs Sales, by Type K Units (2025-2030)
  • Table 618. Africa Gastroparesis Drugs Sales, by Application K Units (2025-2030)
  • Table 619. Africa Gastroparesis Drugs Sales, by End-users K Units (2025-2030)
  • Table 620. Africa Gastroparesis Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 621. Africa Gastroparesis Drugs Sales, by Diagnosis K Units (2025-2030)
  • Table 622. North America Gastroparesis Drugs Sales, by Country K Units (2025-2030)
  • Table 623. North America Gastroparesis Drugs Sales, by Type K Units (2025-2030)
  • Table 624. North America Gastroparesis Drugs Sales, by Application K Units (2025-2030)
  • Table 625. North America Gastroparesis Drugs Sales, by End-users K Units (2025-2030)
  • Table 626. North America Gastroparesis Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 627. North America Gastroparesis Drugs Sales, by Diagnosis K Units (2025-2030)
  • Table 628. United States Gastroparesis Drugs Sales, by Type K Units (2025-2030)
  • Table 629. United States Gastroparesis Drugs Sales, by Application K Units (2025-2030)
  • Table 630. United States Gastroparesis Drugs Sales, by End-users K Units (2025-2030)
  • Table 631. United States Gastroparesis Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 632. United States Gastroparesis Drugs Sales, by Diagnosis K Units (2025-2030)
  • Table 633. Canada Gastroparesis Drugs Sales, by Type K Units (2025-2030)
  • Table 634. Canada Gastroparesis Drugs Sales, by Application K Units (2025-2030)
  • Table 635. Canada Gastroparesis Drugs Sales, by End-users K Units (2025-2030)
  • Table 636. Canada Gastroparesis Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 637. Canada Gastroparesis Drugs Sales, by Diagnosis K Units (2025-2030)
  • Table 638. Mexico Gastroparesis Drugs Sales, by Type K Units (2025-2030)
  • Table 639. Mexico Gastroparesis Drugs Sales, by Application K Units (2025-2030)
  • Table 640. Mexico Gastroparesis Drugs Sales, by End-users K Units (2025-2030)
  • Table 641. Mexico Gastroparesis Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 642. Mexico Gastroparesis Drugs Sales, by Diagnosis K Units (2025-2030)
  • Table 643. Gastroparesis Drugs: by Type(USD/Units)
  • Table 644. Research Programs/Design for This Report
  • Table 645. Key Data Information from Secondary Sources
  • Table 646. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Gastroparesis Drugs: by Type USD Million (2018-2023)
  • Figure 5. Global Gastroparesis Drugs: by Application USD Million (2018-2023)
  • Figure 6. Global Gastroparesis Drugs: by End-users USD Million (2018-2023)
  • Figure 7. Global Gastroparesis Drugs: by Distribution Channel USD Million (2018-2023)
  • Figure 8. Global Gastroparesis Drugs: by Diagnosis USD Million (2018-2023)
  • Figure 9. South America Gastroparesis Drugs Share (%), by Country
  • Figure 10. Asia Pacific Gastroparesis Drugs Share (%), by Country
  • Figure 11. Europe Gastroparesis Drugs Share (%), by Country
  • Figure 12. MEA Gastroparesis Drugs Share (%), by Country
  • Figure 13. North America Gastroparesis Drugs Share (%), by Country
  • Figure 14. Global Gastroparesis Drugs: by Type K Units (2018-2023)
  • Figure 15. Global Gastroparesis Drugs: by Application K Units (2018-2023)
  • Figure 16. Global Gastroparesis Drugs: by End-users K Units (2018-2023)
  • Figure 17. Global Gastroparesis Drugs: by Distribution Channel K Units (2018-2023)
  • Figure 18. Global Gastroparesis Drugs: by Diagnosis K Units (2018-2023)
  • Figure 19. South America Gastroparesis Drugs Share (%), by Country
  • Figure 20. Asia Pacific Gastroparesis Drugs Share (%), by Country
  • Figure 21. Europe Gastroparesis Drugs Share (%), by Country
  • Figure 22. MEA Gastroparesis Drugs Share (%), by Country
  • Figure 23. North America Gastroparesis Drugs Share (%), by Country
  • Figure 24. Global Gastroparesis Drugs: by Type USD/Units (2018-2023)
  • Figure 25. Global Gastroparesis Drugs share by Players 2023 (%)
  • Figure 26. Global Gastroparesis Drugs share by Players (Top 3) 2023(%)
  • Figure 27. Global Gastroparesis Drugs share by Players (Top 5) 2023(%)
  • Figure 28. BCG Matrix for key Companies
  • Figure 29. Allergan, Plc. (Ireland) Revenue, Net Income and Gross profit
  • Figure 30. Allergan, Plc. (Ireland) Revenue: by Geography 2023
  • Figure 31. Abbott Laboratories (Abbott Arzneimittel GmbH) (United States) Revenue, Net Income and Gross profit
  • Figure 32. Abbott Laboratories (Abbott Arzneimittel GmbH) (United States) Revenue: by Geography 2023
  • Figure 33. AstraZeneca Plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. AstraZeneca Plc. (United Kingdom) Revenue: by Geography 2023
  • Figure 35. Cadila Pharmaceuticals Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 36. Cadila Pharmaceuticals Ltd. (India) Revenue: by Geography 2023
  • Figure 37. GlaxoSmithKline Plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 38. GlaxoSmithKline Plc. (United Kingdom) Revenue: by Geography 2023
  • Figure 39. Neurogastrx, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 40. Neurogastrx, Inc. (United States) Revenue: by Geography 2023
  • Figure 41. Valeant Pharmaceuticals International, Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 42. Valeant Pharmaceuticals International, Inc. (Canada) Revenue: by Geography 2023
  • Figure 43. Theravance Biopharma (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 44. Theravance Biopharma (United Kingdom) Revenue: by Geography 2023
  • Figure 45. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 46. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 47. Global Gastroparesis Drugs: by Type USD Million (2025-2030)
  • Figure 48. Global Gastroparesis Drugs: by Application USD Million (2025-2030)
  • Figure 49. Global Gastroparesis Drugs: by End-users USD Million (2025-2030)
  • Figure 50. Global Gastroparesis Drugs: by Distribution Channel USD Million (2025-2030)
  • Figure 51. Global Gastroparesis Drugs: by Diagnosis USD Million (2025-2030)
  • Figure 52. South America Gastroparesis Drugs Share (%), by Country
  • Figure 53. Asia Pacific Gastroparesis Drugs Share (%), by Country
  • Figure 54. Europe Gastroparesis Drugs Share (%), by Country
  • Figure 55. MEA Gastroparesis Drugs Share (%), by Country
  • Figure 56. North America Gastroparesis Drugs Share (%), by Country
  • Figure 57. Global Gastroparesis Drugs: by Type K Units (2025-2030)
  • Figure 58. Global Gastroparesis Drugs: by Application K Units (2025-2030)
  • Figure 59. Global Gastroparesis Drugs: by End-users K Units (2025-2030)
  • Figure 60. Global Gastroparesis Drugs: by Distribution Channel K Units (2025-2030)
  • Figure 61. Global Gastroparesis Drugs: by Diagnosis K Units (2025-2030)
  • Figure 62. South America Gastroparesis Drugs Share (%), by Country
  • Figure 63. Asia Pacific Gastroparesis Drugs Share (%), by Country
  • Figure 64. Europe Gastroparesis Drugs Share (%), by Country
  • Figure 65. MEA Gastroparesis Drugs Share (%), by Country
  • Figure 66. North America Gastroparesis Drugs Share (%), by Country
  • Figure 67. Global Gastroparesis Drugs: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Allergan, Plc. (Ireland)
  • Abbott Laboratories (Abbott Arzneimittel GmbH) (United States)
  • AstraZeneca Plc. (United Kingdom)
  • Cadila Pharmaceuticals Ltd. (India)
  • GlaxoSmithKline Plc. (United Kingdom)
  • Neurogastrx, Inc. (United States)
  • Valeant Pharmaceuticals International, Inc. (Canada)
  • Theravance Biopharma (United Kingdom)
  • Johnson & Johnson (United States)
Additional players considered in the study are as follows:
ETX Pharma, Inc. (United States) , Evoke Pharma (United States)
Select User Access Type

Key Highlights of Report


Feb 2024 218 Pages 68 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Gastroparesis Drugs Market Quantitative research analysis
Global Gastroparesis Drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Allergan, Plc. (Ireland), Abbott Laboratories (Abbott Arzneimittel GmbH) (United States), AstraZeneca Plc. (United Kingdom), Cadila Pharmaceuticals Ltd. (India), GlaxoSmithKline Plc. (United Kingdom), Neurogastrx, Inc. (United States), Valeant Pharmaceuticals International, Inc. (Canada), Theravance Biopharma (United Kingdom) and Johnson & Johnson (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Technological Advancements in the Medical Science" is seen as one of major influencing trends for Gastroparesis Drugs Market during projected period 2023-2030.
The Gastroparesis Drugs market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Gastroparesis Drugs Market Report?

Have a Query? Click Here

Other Related Reports

Octreotide Acetate Comprehensive Study by Type (Immediate-release Injection Form, LAR Depot Form), Application (Medical Therapeutic, Medical Prophylactic), Form (Injectable, Tablets, Capsules, Others...
$ 3350
Vasodilators Comprehensive Study by Type (Arterial Dilators, Venous Dilators, Mixed Dilators), Application (Hypertension, Angina, Heart Failure), Drug Type (Hydralazine, ACE inhibitors, Minoxidil), D...
$ 3650
Cell Isolation/Cell Separation Comprehensive Study by Type (Reagent, Instrument, Others), Application (Biomolecule Isolation, Cancer Research, Stem Cell Research, Tissue Regeneration & Regenerative M...
$ 3750
Psoriasis Treatment Comprehensive Study by Type (Psoriatic Arthritis, Plaque Psoriasis, Others), Route of Administration (Oral, Parenteral, Topical), Distribution Channel (Hospital Pharmacies, Online...
$ 3800
Beta blockers Comprehensive Study by Type (Non-selective antagonists, Selective β1-antagonists), Application (Abnormal Heart Rhythms, Hypertension), Generation (1st Generation, 2nd Generation, 3...
$ 3400
Narcolepsy Treatment Comprehensive Study by Type (Sodium Oxybate, Antidepressants, Central Nervous System Stimulants, Others), Application (Primary Narcolepsy with Cataplexy, Primary Narcolepsy witho...
$ 3750